Related Experiment Video

Updated: Jan 1, 2026

Analysis of Combinatorial miRNA Treatments to Regulate Cell Cycle and Angiogenesis
11:44

Analysis of Combinatorial miRNA Treatments to Regulate Cell Cycle and Angiogenesis

Published on: March 30, 2019

8.0K

LncRNA DLEU1 accelerates the malignant progression of clear cell renal cell carcinoma via regulating miRNA-194-5p

G-Z He1, S-Y Yu, Q-P Zhou

  • 1Department of Ultrasound, University of Chinese Academy of Sciences Shenzhen Hospital, Department of Interventional Ultrasound, Chinese PLA General Hospital, Shenzhen, China. jiemi301@163.com.

European Review for Medical and Pharmacological Sciences
|December 21, 2019
PubMed
Abstract

Insights

Long non-coding RNA DLEU1 promotes clear cell renal cell carcinoma (ccRCC) progression by targeting miRNA-194-5p. High DLEU1 levels correlate with increased metastasis and poorer prognosis in ccRCC patients.

Area of Science:

  • Oncology
  • Molecular Biology
  • Genetics

Background:

  • Clear cell renal cell carcinoma (ccRCC) is a significant cause of cancer-related mortality.
  • Understanding the molecular mechanisms driving ccRCC progression is crucial for developing targeted therapies.

Purpose of the Study:

  • To investigate the role of long non-coding RNA (lncRNA) DLEU1 in ccRCC pathogenesis.
  • To elucidate the regulatory relationship between DLEU1 and microRNA-194-5p (miRNA-194-5p) in ccRCC.

Main Methods:

  • Quantitative Real Time-Polymerase Chain Reaction (qRT-PCR) to assess DLEU1 expression in ccRCC tissues.
  • In vitro studies evaluating cell proliferation and migration after DLEU1 manipulation.
  • Dual-Luciferase reporter gene assay and rescue experiments to confirm DLEU1-miRNA-194-5p interaction.

Main Results:

  • DLEU1 expression is significantly upregulated in ccRCC tissues compared to adjacent normal tissues.
  • High DLEU1 levels are associated with increased lymphatic and distant metastasis and poorer patient prognosis.
  • DLEU1 knockdown inhibits ccRCC cell proliferation and migration; miRNA-194-5p is identified as a direct target of DLEU1.
  • MiRNA-194-5p inhibition reverses the pro-metastatic effects of DLEU1 in ccRCC cells.

Conclusions:

  • DLEU1 acts as an oncogenic lncRNA in ccRCC, promoting tumor progression and metastasis.
  • The DLEU1/miRNA-194-5p axis plays a critical role in ccRCC pathogenesis.
  • DLEU1 may serve as a potential therapeutic target for ccRCC treatment.

More Related Videos

Sequencing Small Non-coding RNA from Formalin-fixed Tissues and Serum-derived Exosomes from Castration-resistant Prostate Cancer Patients12:13

Sequencing Small Non-coding RNA from Formalin-fixed Tissues and Serum-derived Exosomes from Castration-resistant Prostate Cancer Patients

Published on: November 19, 2019

7.1K

Related Concept Videos

lncRNA - Long Non-coding RNAs02:39

lncRNA - Long Non-coding RNAs

In humans, more than 80% of the genome gets transcribed. However, only around 2% of the genome codes for proteins. The remaining part produces non-coding RNAs which includes ribosomal RNAs, transfer RNAs, telomerase RNAs, and regulatory RNAs, among other types. A large number of regulatory non-coding RNAs have been classified into two groups depending upon their length – small non-coding RNAs, such as microRNA, which are less than 200 nucleotides in length, and long non-coding RNA...
9.7K
MicroRNAs01:22

MicroRNAs

MicroRNA (miRNA) are short, regulatory RNA transcribed from introns—non-coding regions of a gene—or intergenic regions—stretches of DNA present between genes. Several processing steps are required to form biologically active, mature miRNA. The initial transcript, called primary miRNA (pri-mRNA), base-pairs with itself forming a stem-loop structure. Within the nucleus, an endonuclease enzyme, called Drosha, shortens the stem-loop structure into hairpin-shaped pre-miRNA. After...
23.8K
MicroRNAs01:22

MicroRNAs

MicroRNA (miRNA) are short, regulatory RNA transcribed from introns (non-coding regions of a gene) or intergenic regions (stretches of DNA present between genes). Several processing steps are required to form biologically active, mature miRNA. The initial transcript, called primary miRNA (pri-mRNA), base-pairs with itself, forming a stem-loop structure. Within the nucleus, an endonuclease enzyme, called Drosha, shortens the stem-loop structure into hairpin-shaped pre-miRNA. After the pre-miRNA...
3.7K
Abnormal Proliferation02:23

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
5.0K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
4.5K
Tumor Progression02:07

Tumor Progression

Tumor progression is a phenomenon where the pre-formed tumor acquires successive mutations to become clinically more aggressive and malignant. In the 1950s, Foulds first described the stepwise progression of cancer cells through successive stages.
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
7.2K